- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00473200
Effect of S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine
Effect of Oral S-adenosylmethionine (SAMe) on Blood Levels of Homocysteine in Human Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to investigate whether S-adenosylmethionine (SAMe), a natural substance available as a nutritional supplement, can influence blood levels of homocysteine (Hcy). More specifically, we will determine if chronic oral SAMe administration effects homocysteine metabolism in patients with vascular disease who have mild to moderate hyperhomocysteinemia through the following specific aims:
Specific Aim 1 - To determine the effect of oral SAMe (1200 mg/day) on plasma total homocysteine levels in subjects with mild to moderate hyperhomocysteinemia.
Specific Aim 2 - To determine the effect of oral SAMe (1200 mg/day) with and without supplementation of folate, vitamin B12 and B6, on plasma homocysteine levels in patients with mild to moderate hyperhomocysteinemia.
Specific Aim 3 - To determine the effect of oral SAMe (1200 mg/day) on plasma levels pf asymmetric dimethylarginine (ADMA) in subjects with mild to moderate hyperhomocysteinemia.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75204
- Baylor University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age and older
- Must have a serum homocysteine value greater than or equal to 14 μmol/L
- Stable weight 3 months prior to study participation
Exclusion Criteria:
- Subjects with a BMI greater than 35 or less than 18
- Currently taking B 100 or other high-dose B vitamin supplements within the past 12 months
- Taken methionine or SAMe supplements within the past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
1200 mg daily
|
Active Comparator: S-adenosylmethionine
|
1200 mg daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the effect of oral SAMe (1200 mg/day) on plasma total homocysteine (tHcy) and asymmetric dimethylagrinine (ADMA) levels in subjects with mild to moderate hyperhomocysteinemia.
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the effect of oral SAMe (1200 mg/day) with and without supplementation of folate, vitamin B12 and B6, on plasma homocysteine levels in patients with mild to moderate hyperhomocysteinemia.
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Teodoro Bottiglieri, PhD, Baylor Research Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 005-210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperhomocysteinemia
-
Radboud University Medical CenterCompletedMild HyperhomocysteinemiaNetherlands
-
Istanbul Medeniyet UniversityCompletedEpilepsy | Ischemic Stroke | Hyperhomocysteinemia, Thrombotic, Cbs-RelatedTurkey
-
University of Novi Sad, Faculty of Sport and Physical...Completed
-
Queen Sirikit National Institute of Child HealthChulalongkorn UniversityCompletedObesity | HyperhomocysteinemiaThailand
-
Center for Health, Exercise and Sport Sciences,...Completed
-
London School of Hygiene and Tropical MedicineCompletedHyperhomocysteinemia | Micronutrient DeficienciesGambia
-
National Institute of Cardiology, Laranjeiras,...CompletedEndothelial Dysfunction | HyperhomocysteinemiaBrazil
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesRecruiting
-
Huilian ZhuNot yet recruiting
-
Peking UniversityNational Natural Science Foundation of China; Institute of reproductive and...CompletedHyperhomocysteinemiaChina
Clinical Trials on S-adenosylmethionine
-
US Department of Veterans AffairsCompleted
-
University of California, DavisNational Institute on Alcohol Abuse and Alcoholism (NIAAA); University of Colorado... and other collaboratorsCompleted
-
Medical University of WarsawNational Science Centre, PolandRecruitingPrimary Sclerosing Cholangitis (PSC)Poland
-
Cedars-Sinai Medical CenterJarrow Formulas IncNot yet recruitingColorectal Cancer | Liver Metastases | Liver Metastasis Colon Cancer | Liver Injury | Sinusoidal Obstruction Syndrome | 5-Fluorouracil Toxicity | Liver Toxicity, Chemically-InducedUnited States
-
VA Office of Research and DevelopmentCompleted
-
Institute of Liver and Biliary Sciences, IndiaCompletedNon-alcoholic SteatohepatitisIndia
-
Shiga UniversityUniversity of Chicago; Shionogi; Tokyo University; Showa University; Fukushima Medical... and other collaboratorsUnknown
-
Boston Scientific CorporationCompletedTachycardia, VentricularUnited Kingdom, Denmark, Italy, New Zealand, Germany, France, Netherlands, Portugal, Czechia, Spain
-
First Affiliated Hospital of Zhejiang UniversityRecruiting
-
University Hospital, ToulouseCompleted